Medivate Partners

Cipherome is a biotechnology company dedicated to personalized medicine. It aims to tailor drug treatments to individual patients by leveraging its proprietary platform that combines genetics and other factors. The company's mission is to reduce serious adverse drug reactions by identifying the most suitable medication for each person, regardless of age, race, or gender.

SoVarGen is a biotechnology company focused on the discovery and development of novel therapeutics and diagnostics for central nervous system diseases. The company targets neurological disorders, including conditions driven by low-level somatic mutations, and aims to overcome limitations of current brain disease treatment development to bring effective therapies to patients more quickly.

Artiva Biotherapeutics, Inc. is a San Diego-based biotechnology company focused on developing and manufacturing cellular immunotherapies for cancer treatment. Founded in 2019, Artiva specializes in off-the-shelf, allogeneic natural killer (NK) cell therapies aimed at treating both hematologic cancers and solid tumors. The company's product pipeline includes therapies that target CD20 and CD19 in B-cell lymphomas, as well as HER2 in various solid tumors. Artiva is committed to harnessing the therapeutic potential of NK cells while addressing challenges in their scalability and manufacturing. Its mission centers on delivering effective and safe cell therapies that are readily accessible to cancer patients in need.

Cognate BioServices, Inc. is a Memphis, Tennessee-based company specializing in the development and manufacturing of cell and cell-mediated gene therapy products for biotechnology firms and institutions across the United States. Founded in 2002, the company operates as a fully-integrated contract bioservices organization, offering a wide range of services that include process development, regulatory support, assay development, preclinical services, and cell banking. Cognate BioServices is recognized for its expertise in manufacturing cell-based products under current Good Manufacturing Practice (cGMP) conditions, and it employs advanced techniques in cryopreservation and cell isolation and expansion. The company is strategically partnered with Akron Biotechnology, which enhances its capabilities in serving the biotechnology sector.

WindMIL Therapeutics, Inc. is a biotechnology company focused on developing innovative cell therapies for cancer treatment. Established in 2015 and based in Baltimore, Maryland, the company specializes in translating insights from bone marrow immunology into effective therapeutic solutions. WindMIL Therapeutics utilizes its proprietary platform to create a new class of cell therapies known as Marrow Infiltrating Lymphocytes (MILs), which are derived from memory T cells found in the bone marrow. These therapies leverage re-activated T-cells that are typically dormant, harnessing the unique immunologic properties of the bone marrow to enhance cancer immunotherapy. Through its advancements, WindMIL Therapeutics aims to provide life-saving treatments for cancer patients, addressing a critical need in oncology.

Cognate BioServices, Inc. is a Memphis, Tennessee-based company specializing in the development and manufacturing of cell and cell-mediated gene therapy products for biotechnology firms and institutions across the United States. Founded in 2002, the company operates as a fully-integrated contract bioservices organization, offering a wide range of services that include process development, regulatory support, assay development, preclinical services, and cell banking. Cognate BioServices is recognized for its expertise in manufacturing cell-based products under current Good Manufacturing Practice (cGMP) conditions, and it employs advanced techniques in cryopreservation and cell isolation and expansion. The company is strategically partnered with Akron Biotechnology, which enhances its capabilities in serving the biotechnology sector.

Genopis specializes in plasmid DNA based technology and provides contract development and manufacturing organization (CDMO) opportunities to help your company reach its clinical and commercial goals.

SillaJen, Inc. is a biotechnology company based in Busan, South Korea, with additional offices in Seoul and San Francisco. Established in 2006, SillaJen specializes in the development and commercialization of oncolytic immunotherapy products, leveraging its proprietary SOLVE™ platform. The company's lead product, Pexa-Vec, is currently undergoing Phase III clinical trials for the treatment of advanced liver cancer. In addition to Pexa-Vec, SillaJen is advancing other therapies, including JX-929, which targets breast, colorectal, and pancreatic cancers, and JX-970, aimed at specific tumor tissues. The company also has a series of modified vaccinia vaccines under the JX-900 designation. SillaJen has entered into cooperative research agreements with the National Cancer Institute to explore combination therapies for colorectal cancer. Through these efforts, SillaJen aims to enhance treatment options for various cancers, utilizing innovative oncolytic approaches.

WCCT Global is a provider of outsourced early drug development services tailored for the pharmaceutical, biotechnology, and medical device sectors. The company specializes in clinical study services, offering comprehensive support that includes regulatory guidance, program management, patient recruitment, and data management. Additionally, WCCT Global focuses on strategic consulting, particularly for special disease populations, pediatric groups, and areas such as ethno-bridging and cardiac safety. By acting as a development partner, the company aims to enhance the efficiency and effectiveness of clinical trials.